Vilas P Sabale
Research Subjects
Vilas P Sabale has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Gaurang R Shah
Jivdaya Hospital, Dharmoday bldg, Jivdaya lane, L.B.S. Marg, Ghatkopar (West), Mumbai 400 086, India
1 shared publication - Manojkumar V Chaudhari
Bhaghirathi Medical Foundation, 169, Parvati gaon, Pune, 400 009, India
1 shared publication Navneet A Sonawane
Clinical Operations, Vedic Lifesciences Pvt. Ltd., B-118, Morya House, Link Road, Andheri (West), Mumbai, 400 053, India
1 shared publication- Shrikant V Pensalwar
Balaji Clinic, Devi Pada, Main Road, Borivali (East), Mumbai, 400 066, India
1 shared publication - Suresh Patankar
Institute of Urology, 32/2A, Erandwane, Gulwani Maharaj Road, Pune, 400 009, India
1 shared publication
Latest Publications
- Open Access
- 15 September 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 155
Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study
Background: Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) – a proprietary polyherbal preparation for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study. Methods: 78 men aged 25–50 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy. Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigator’s Global assessment and Subjects’ opinion. Results: In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P < 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigator’s global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subject’s rating for tolerability of treatment was similar in both groups. Conclusions: VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men. Trial Registration: Clinical Trial Registry India, CTRI/2009/091/000099, 31-03-2009
- 15 September 2012
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 12 (1) , 155
Open AccessEvaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study
Background: Evidence is lacking for multi-ingredient herbal supplements claiming therapeutic effect in sexual dysfunction in men. We examined the safety and efficacy of VigRX Plus (VXP) – a proprietary polyherbal preparation for improving male sexual function, in a double blind, randomized placebo-controlled, parallel groups, multi-centre study. Methods: 78 men aged 25–50 years of age; suffering from mild to moderate erectile dysfunction (ED), participated in this study. Subjects were randomized to receive VXP or placebo at a dose of two capsules twice daily for 12 weeks. The international index of erectile function (IIEF) was the primary outcome measure of efficacy. Other efficacy measures were: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS), Serum testosterone, Semen analysis, Investigator’s Global assessment and Subjects’ opinion. Results: In subjects receiving VXP, the IIEF-Erectile Function (EF) scores improved significantly as compared to placebo. After 12 weeks of treatment, the mean (sd) IIEF-EF score at baseline increased from 16.08 (2.87) to 25.08 (4.56) in the VXP group versus 15.86 (3.24) to 16.47 (4.25) in the placebo group (P < 0.0001). Similar results were observed in each of the remaining four domains of the IIEF (orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction).There was a significant difference for VXP versus placebo comparison of mean (sd) EDITS scores of patients: 82.31(20.23) vs 36.78(22.53) and partners :(82.75(9.8) vs 18.50(9.44);P < 0.001. Thirty-five out of 39 (90%) subjects from the VXP group and one (3%) from the placebo group wished to continue with the treatment they received. Investigator’s global assessment rated VXP therapy as very good to excellent in more than 50% patients and placebo therapy as fair to good in about 25% of patients. Incidence of side effects and subject’s rating for tolerability of treatment was similar in both groups. Conclusions: VigRX Plus was well tolerated and more effective than placebo in improving sexual function in men. Trial Registration: Clinical Trial Registry India, CTRI/2009/091/000099, 31-03-2009